Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Vascular events with selective COX2 inhibitors and NSAIDs: analyzing the risks

Nature Clinical Practice Cardiovascular Medicine volume 3, pages 586–587 (2006)Cite this article

boxed-textKearney PM et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332: 1302–1308

While evidence confirms increased cardiovascular toxicity with COX2 inhibitors, further information is required to assess the importance of specific drugs, dosage, patient phenotype and possibly genotype more accurately

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Moher D et al. (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354: 1896–1900

    Article  CAS  Google Scholar 

  2. Joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, volume III. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. [http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4090T3.htm] (accessed 21 June 2006)

  3. Bombardier C et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520–1528

    Article  CAS  Google Scholar 

  4. Woloshin S et al. (2005) Where the naproxen story went wrong. Washington Post, Feb 1 2005

  5. Brophy JM (2005) Celecoxib and cardiovascular risks. Expert Opin Drug Saf 4: 1005–1015

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Carol Lovegrove, Freelance Medical Writer.

Author information

Authors and Affiliations

  1. Associate Professor of Medicine at McGill University and the University of Montreal and Director of the McGill University Health Centre (MUHC)/Centre hospitalier de lUniversité de Montréal (CHUM) Technology Assessment Unit at the Royal Victoria Hospital, Montreal, QC, Canada

    James M Brophy

Authors
  1. James M Brophy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James M Brophy.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brophy, J. Vascular events with selective COX2 inhibitors and NSAIDs: analyzing the risks. Nat Rev Cardiol 3, 586–587 (2006). https://doi.org/10.1038/ncpcardio0684

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0684

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing